This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Former Customers Of Allscripts MyWay™ Praise Aprima For Fast, Smooth, And Efficient Upgrade

Another new Aprima customer confirmed the program is indeed a genuine rescue. "We were nervous about how much work it might be and what could go wrong, but everything went just as Aprima promised – easy," said the practice's administrator. The practice was alerted to the Aprima Rescue Plan by a very prominent EHR reseller in the healthcare field, who has requested not to be named.

"This was a very smooth transition for our customer; the upgrade was seamless and staff loved the new system," stated the reseller. "The added functionality is also extremely helpful to our customers. Aprima does everything I have been asking for in Allscripts MyWay™ and more."

"We actually could have upgraded these and other practices even faster, but we knew we had a very frustrated and outraged set of new customers coming on board. Before rollout, we performed extensive and repeated testing, and these early successes are exactly what we expected," said Michael Nissenbaum, Aprima president and CEO.  He continued, "The volume of upgrades ahead of us is huge, and our new customers can be sure we'll remain just as focused and vigilant in making sure the 100 th and 1,000 th transition go just as well as the first ones. We appreciate the faith these providers have placed in Aprima and look forward to serving them for many years to come."

Aprima Rescue Plan for customers of Allscripts MyWay includes:

  • Free Aprima licenses for each Allscripts MyWay license – no need to repurchase software; up to an $8,500 savings per provider
  • Similar look and feel; Aprima has made nearly 1,000 enhancements since it licensed the original source code to Allscripts in 2008, including hundreds of substantive improvements to the PM system
  • Minimal learning curve, since it is only needed for the new features
  • Minimal downtime compared to what is typical when changing systems and having to re-learn many new workflows
  • Existing data remains intact; this is a proven product upgrade, not a conversion
  • U.S.-based support

For more information, or to sign up for the Aprima Rescue Plan for customers of Allscripts MyWay , visit www.aprima.com/rescue, call 866-960-6890, option 7, or email rescue@aprima.com.

About Aprima Medical Software, Inc.

Aprima provides innovative electronic health record, practice management and revenue cycle management solutions for medical practices. The Aprima EHR/PM is an integrated system built on a single database. Aprima uses a fast, flexible design that adapts automatically to a physician's workflow and sets the benchmark for ease-of-use, speed, and flexibility. Aprima is one of the few companies with a 14-year track record of success, including CCHIT Certification consistently every year as well as ONC Certification for 2011/2012. Thousands of Aprima users are benefiting from improved quality of care, improved patient satisfaction, improved quality of life and an improved bottom line. Based in Carrollton, TX, Aprima performs all development, support, and implementation from the U.S. To learn more about how Aprima can help your practice, please visit www.aprima.com, call us at 866-960-6890, option 7, or email us at info@aprima.com.

Contact: Judy Friedman jfriedman@aprima.com (214) 466-8093

SOURCE Aprima Medical Software, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs